Aminoacylase-1 Deficiency (ACY1 Deficiency)

Aminoacylase-1 deficiency is a very rare inherited metabolic condition. In this disorder, the body’s enzyme called aminoacylase-1 does not work well. This enzyme normally removes a small chemical tag (an acetyl group) from “tagged” amino acids, so the body can reuse those amino acids. When the enzyme is weak or missing, many N-acetylated amino acids build up and spill into the urine. Some people develop neurological problems like developmental delay, low muscle tone, seizures, or movement difficulties, but others can have few or no symptoms. The severity varies a lot from person to person. MedlinePlus+2Orpha+2

Aminoacylase-1 deficiency is a rare inherited metabolic condition. It happens when changes (mutations) in the ACY1 gene reduce or stop the action of the enzyme aminoacylase-1. This enzyme normally helps remove an “acetyl cap” from certain small building blocks of proteins (amino acids) so the body can reuse them. When the enzyme does not work well, many N-acetylated amino acids build up and appear in the urine. Doctors often find the problem by testing urine with specialized methods (gas chromatography–mass spectrometry) and then confirming the gene change with DNA testing. Symptoms vary a lot. Some people have delayed milestones, low muscle tone, movement problems, learning differences, or seizures; others can be very mildly affected or even show few or no clear symptoms. The condition is autosomal recessive, which means a child is affected when both parents silently carry one non-working copy of ACY1. Mayo Clinic Laboratories+3Orpha+3MedlinePlus+3

How the problem starts

Amino acids are the building blocks of proteins. The body sometimes “parks” amino acids temporarily by adding an acetyl tag. The aminoacylase-1 (ACY1) enzyme removes that tag so the amino acid can be used again. If ACY1 is not working because of gene changes, the tagged amino acids cannot be recycled properly. As a result, they accumulate and are seen in high amounts in urine tests. Doctors recognize this pattern—high N-acetylated amino acids—as a biochemical “signature” of this condition. Cell+1

Other names

Aminoacylase-1 deficiency has been described with a few similar names in the medical literature:

• ACY1 deficiency or ACY1D

• Aminoacylase I deficiency (Roman numeral “I”)

• Inborn error of metabolism with urinary N-acetyl aminoaciduria (descriptive phrase)

These terms all point to the same condition involving the ACY1 gene and enzyme. MedlinePlus+2National Organization for Rare Disorders+2

Types

There is no strict, universal “type” system, but doctors often group people by clinical presentation because symptoms can be very different. These groupings help families and clinicians talk about what they see:

1. Asymptomatic biochemical form – Some people have the urine pattern of ACY1 deficiency on testing but no clear health problems related to it. This has been reported in the medical literature. MedlinePlus

2. Developmental-delay predominant form – The most common pattern is delays in motor and/or speech milestones with low muscle tone (hypotonia). Severity ranges from mild to moderate. MedlinePlus+1

3. Seizure-associated form – Some individuals have epileptic seizures, often along with developmental issues. Seizures may cluster with intercurrent illness in some reports. MalaCards

4. Movement-disorder predominant form – A smaller number have dystonia (twisting movements) and signs of basal ganglia involvement on MRI; some also show hypomyelination. PubMed

5. Mixed neurologic form – Many people show a mixture of the above features (for example, developmental delay plus seizures and movement problems). This variability is a key feature of ACY1 deficiency. Orpha

These are descriptive patterns based on published cases, not rigid subtypes. A person’s course can be milder or more complex than any single label suggests.

Causes

Root cause: Aminoacylase-1 deficiency happens when a person inherits two non-working copies of the ACY1 gene (one from each parent). This is called autosomal recessive inheritance. The gene problem stops or reduces the enzyme activity, which leads to the biochemical pattern and (in some people) neurologic issues. NCBI+1

Below are 20 clear, accurate “causes and contributors.” The first items are direct genetic causes; later items cover mechanisms, inheritance situations, and risk contributors that help explain why and how the disease appears.

1. Biallelic ACY1 variants (autosomal recessive) – Two pathogenic changes in ACY1 are required for disease. NCBI

2. Loss-of-function mutations – Changes that stop the enzyme from working (for example, nonsense, frameshift, or certain splice-site variants). Orpha

3. Missense mutations – Single-letter DNA changes that alter the enzyme’s shape or activity (some reduce activity significantly). AME Case Reports

4. Splice-site variants – Changes that disrupt how the gene’s message is processed, producing a faulty enzyme. Cell

5. Small insertions/deletions – Tiny DNA gains or losses that shift the reading frame and impair the protein. Cell

6. Larger gene deletions/duplications – Less common structural changes that remove or duplicate part of ACY1, leading to deficiency. (Documented generally in metabolic genetics; specific ACY1 CNVs are rare but mechanistically plausible.) NCBI

7. Homozygosity due to parental relatedness – When parents share ancestry, the chance of inheriting the same rare variant increases. (Reported in case series of rare metabolic diseases, including ACY1.) RCPCH Child Protection Portal

8. Compound heterozygosity – Two different ACY1 variants (one on each copy) can combine to reduce enzyme function enough to cause disease. Cell

9. Recurrent pathogenic variants – Some specific changes (for example, c.1057C>T (p.Arg353Cys)) have been reported in multiple affected individuals. AME Case Reports

10. Protein misfolding – Some missense variants make the enzyme unstable so it breaks down faster in cells. Cell

11. Active-site disruption – Variants can directly alter the part of the enzyme that removes the acetyl tag, weakening activity. Cell

12. Reduced enzyme levels – Certain variants may lower the amount of ACY1 made, not just its function. Cell

13. Impaired cellular trafficking – The altered enzyme may not reach the right place inside the cell, reducing its effect. Cell

14. Metabolic stress unmasking symptoms – Illness, fever, or fasting can stress the nervous system and reveal seizures or regressions in vulnerable individuals. (Observed broadly in inborn errors; also noted in summaries of ACY1D.) MalaCards

15. Gene–environment interplay – Nutrition, infections, and general health may modify how strongly symptoms show up, even with the same variants. (Explains variable expressivity described across reports.) Orpha

16. Modifier genes – Other genes may slightly change severity, which helps explain why some people are asymptomatic while others have neurological signs. Orpha

17. Developmental timing – The nervous system is sensitive during infancy and early childhood; enzyme deficiency during these windows may have bigger effects on milestones. BMJ ADC

18. Brain circuit vulnerability – Areas like the basal ganglia can be involved, which relates to movement symptoms in some patients. PubMed

19. Hypomyelination association – Some MRI studies describe reduced myelin development, which can contribute to slower motor or cognitive progress. PubMed

20. Natural variability in phenotype – Even with the same biochemical signature, people can range from no symptoms to clear neurologic problems; this variability itself is a “cause” of different presentations. MedlinePlus

Symptoms

Not everyone has all of these symptoms. Some people have none. These are the most commonly reported features, each in plain language:

1. Developmental delay – Sitting, standing, walking, or talking later than peers. This is often the first concern parents notice. MedlinePlus

2. Low muscle tone (hypotonia) – The body feels “floppy,” and babies may have poor head control or slouch more. MedlinePlus

3. Motor delay – Difficulty with coordinated movements, running, or fine motor tasks like using utensils. MedlinePlus

4. Mild intellectual disability – Learning may be slower, and academic skills may need extra support. MedlinePlus

5. Seizures – Episodes of abnormal electrical activity in the brain; types and frequency can vary. MedlinePlus

6. Movement problems – Stiffness, abnormal postures, or twisting movements (dystonia) have been reported in some individuals. PubMed

7. Speech delay or sound disorder – First words and clear articulation may come later than expected. PMC

8. Behavioral or autistic features – Some people show social communication differences, repetitive behaviors, or attention problems. PMC

9. Coordination problems – Clumsiness or trouble with balance-based activities (for example, hopping or tandem walking). MedlinePlus

10. Fatigability – Getting tired more easily with activity, often related to hypotonia and motor effort. (Clinical inference consistent with hypotonia/motor findings.) MedlinePlus

11. Variably normal development – Some people meet milestones on time and remain well; they are found only because a test picked up the urine pattern. MedlinePlus

12. Irritability during illness – When sick, some may have more neurologic symptoms, including seizures. MalaCards

13. Attention and learning challenges – School tasks may need accommodations; strengths and weaknesses are individualized. PMC

14. Subtle MRI brain changes – Imaging may be normal or may show mild cortical atrophy, hypomyelination, or basal ganglia signs that relate to symptoms. OMMBID+1

15. Overall variability – The same diagnosis can look very different between people, from asymptomatic to combined motor, cognitive, and seizure issues. Orpha

Diagnostic tests

Doctors do not rely on one test alone. They combine clinical evaluation, biochemical testing, genetic analysis, and sometimes EEG or MRI to understand the whole picture. Below, the tests are grouped as requested.

A) Physical exam

1. General pediatric and neurologic exam – The clinician checks growth, head size, muscle bulk, reflexes, strength, and coordination to spot signs like hypotonia or delayed milestones. This gives a baseline for follow-up. MedlinePlus

2. Tone assessment – The examiner gently moves the limbs to feel how “loose” or “stiff” the muscles are. Hypotonia fits common ACY1 presentations. MedlinePlus

3. Developmental milestone review – A structured discussion and observation of sitting, walking, talking, and self-care skills helps quantify delay and guide therapies. MedlinePlus

4. Gait and balance observation – Watching the child walk, turn, and stand on one foot can uncover coordination or movement-disorder clues. MedlinePlus

5. Behavioral/communication screening – Simple clinic-based tools or observations can flag attention issues or autistic features for more formal evaluation. PMC

B) Manual bedside/office tests

6. Deep tendon reflex testing – A reflex hammer check helps distinguish low tone from weak reflexes or other patterns that may suggest central vs peripheral involvement.

7. Romberg test – Standing with feet together, eyes open then closed, helps screen balance pathways; sway suggests sensory or cerebellar contribution to coordination problems.

8. Finger-to-nose and heel-to-shin – Simple coordination tests that can show dysmetria or clumsiness common in motor delays.

9. Tandem gait (heel-to-toe walking) – A sensitive check for balance and coordination that often reveals subtle problems even when casual walking looks normal.

10. Standardized developmental screening (e.g., simple office tools) – Short, hands-on tasks and parent questionnaires provide a snapshot of motor and language function and guide referrals to early intervention.

(These bedside tests are routine neurology tools that help describe function; they complement, but do not replace, the biochemical and genetic tests below.)

C) Laboratory and pathological tests

11. Urine organic acids by GC-MS – The hallmark test. It shows high N-acetylated amino acids (for example, N-acetyl-alanine, N-acetyl-glycine, N-acetyl-methionine, N-acetyl-glutamic acid). This biochemical “fingerprint” strongly suggests ACY1 deficiency. Mayo Clinic Laboratories+1

12. Dedicated urine N-acetyl amino acid panel – A quantitative panel confirms and measures specific N-acetylated amino acids; modern labs report a clear pattern to support diagnosis. Mayo Clinic Laboratories

13. Plasma amino acids – Often normal, but can help rule out other aminoacidopathies and ensure the metabolic survey is complete. (Common practice in metabolic evaluations of suspected inborn errors.)

14. Genetic testing: ACY1 gene sequencing – Detects pathogenic variants in the ACY1 gene and confirms the diagnosis. Testing can be targeted (after the urine result) or part of a larger neurodevelopmental/metabolic gene panel. NCBI

15. Copy-number analysis (exon-level CNV) – Looks for larger deletions/duplications in ACY1 if sequencing is negative but suspicion remains. (General genetic best practice for rare metabolic genes.) NCBI

16. Family/segregation testing – Testing parents helps confirm autosomal recessive inheritance and informs recurrence risk for future pregnancies. NCBI

17. (Research/limited) Enzyme activity assays – In certain centers, ACY1 activity may be studied in cells; this is less common clinically but supports pathogenicity in unclear cases. Medlink

D) Electrodiagnostic tests

18. EEG (electroencephalogram) – If seizures are suspected, EEG records brain waves to detect epileptic activity and guide anti-seizure treatment choices. (Seizures are reported in ACY1D.) MedlinePlus

19. EMG/nerve conduction (selected cases) – If there is unusual weakness or suspected peripheral nerve involvement, these tests check muscle and nerve function. They are not routine for everyone but can clarify complex presentations.

E) Imaging tests

20. Brain MRI – MRI may be normal or may show findings like mild cortical atrophy, hypomyelination, or basal ganglia changes in some patients, which can align with movement problems (such as dystonia). MRI helps exclude other causes and document brain development over time. OMMBID+1

Non-pharmacological treatments (therapies & others)

Note: These are general supportive options used based on individual needs. Not every person will need all of them. Evidence for ACY1D-specific benefit is limited; choices are guided by symptoms and standard neurodevelopmental care.

1. Care coordination with a metabolic/genetics team
   Purpose: Build a unified plan across specialties.
   Mechanism: Regular reviews align neurology, rehab, nutrition, and education supports, catching issues early and avoiding conflicting advice. GARD Information Center

2. Developmental early-intervention services
   Purpose: Boost motor, language, social, and cognitive skills in infancy/early childhood.
   Mechanism: Frequent, play-based learning strengthens neural pathways when the brain is most adaptable (neuroplasticity). MedlinePlus

3. Physiotherapy (physical therapy)
   Purpose: Improve posture, strength, balance, and mobility if hypotonia or motor delay are present.
   Mechanism: Task-specific, repetitive movement training enhances motor control and prevents secondary contractures. MedlinePlus

4. Occupational therapy
   Purpose: Support daily living skills (feeding, dressing, handwriting) and fine-motor coordination.
   Mechanism: Gradual skill shaping, adaptive tools, and sensory strategies to increase functional independence. MedlinePlus

5. Speech-language therapy
   Purpose: Support speech clarity, language understanding/expression, and social communication.
   Mechanism: Structured practice, augmentative and alternative communication (AAC) when needed, and parent-led home programs. MedlinePlus

6. Feeding and swallowing therapy
   Purpose: Improve safe feeding and growth if oral-motor issues occur.
   Mechanism: Posture, pacing, texture changes, and oral-motor exercises to reduce aspiration risk and improve calorie intake. MedlinePlus

7. Behavioral therapy (e.g., CBT/ABA-informed strategies)
   Purpose: Manage attention, behavior, anxiety, or adaptive skills.
   Mechanism: Positive reinforcement, structured routines, and coping skills training. MedlinePlus

8. Individualized Education Plan (IEP) / special education supports
   Purpose: Ensure appropriate learning goals and classroom accommodations.
   Mechanism: Legally supported school plans align teaching strategies with a child’s specific strengths and needs. MedlinePlus

9. Seizure safety education
   Purpose: Reduce injury and emergency risk if seizures occur.
   Mechanism: Home and school safety plans, recognition of triggers (fever, sleep loss), and rescue protocols. MedlinePlus

10. Good sleep hygiene
    Purpose: Stabilize mood, attention, and seizure threshold.
    Mechanism: Consistent schedules, dark/quiet rooms, and behavioral sleep routines improve sleep architecture. MedlinePlus

11. Regular physical activity (age-appropriate)
    Purpose: Improve tone, endurance, and mood.
    Mechanism: Aerobic and strengthening activities enhance neuroplasticity and cardiorespiratory health. MedlinePlus

12. Assistive technology
    Purpose: Enhance communication, learning, and mobility.
    Mechanism: AAC devices, educational software, or mobility aids reduce barriers and increase participation. MedlinePlus

13. Nutrition counseling (balanced diet)
    Purpose: Support growth and energy without unnecessary restrictions.
    Mechanism: A registered dietitian monitors calories, protein adequacy, and micronutrients; no ACY1-specific diet is currently proven. Medlink

14. Social work support
    Purpose: Navigate services, insurance, and benefits; reduce caregiver stress.
    Mechanism: Resource linkage and counseling. GARD Information Center

15. Mental health support for caregivers
    Purpose: Protect caregiver well-being and resilience.
    Mechanism: Counseling, peer groups, and respite care reduce burnout. GARD Information Center

16. Genetic counseling
    Purpose: Explain inheritance, recurrence risk, and testing options for family members.
    Mechanism: Carrier testing and reproductive counseling (e.g., prenatal or preimplantation options). MedlinePlus

17. Regular hearing and vision checks
    Purpose: Identify treatable sensory contributors to language or motor delays.
    Mechanism: Early correction (glasses, hearing aids) supports learning. MedlinePlus

18. Immunization on schedule
    Purpose: Reduce fever/infection-related setbacks and seizure triggers.
    Mechanism: Vaccines lower risk of preventable illnesses that can worsen neurologic symptoms. MedlinePlus

19. Emergency care plan
    Purpose: Guide urgent care teams during seizures or acute illness.
    Mechanism: A written plan lists diagnosis, medications, and clinician contacts for rapid, appropriate care. GARD Information Center

20. Community and rare-disease support organizations
    Purpose: Education and peer support.
    Mechanism: Patient groups help families learn practical strategies and find specialists familiar with rare metabolic disorders. Metabolic Support UK

---

Drug treatments

Important: There is no proven, ACY1-specific medication that corrects the enzyme problem. Drug use is individualized to symptoms (e.g., seizures, dystonia, sleep issues). Doses and timing must be set by your clinician. Below are commonly used categories and examples to discuss with your care team.

1. Antiseizure medicines (e.g., levetiracetam, valproate, lamotrigine)
   Purpose: Reduce seizure frequency and severity if epilepsy is present.
   Mechanism: Stabilize neuronal excitability through ion channels or neurotransmitter modulation. MedlinePlus

2. Rescue seizure therapy (e.g., intranasal midazolam or diazepam)
   Purpose: Stop prolonged or cluster seizures outside the hospital.
   Mechanism: Rapid GABAergic inhibition aborts ongoing seizures. MedlinePlus

3. Anti-dystonia / spasticity agents (e.g., baclofen, tizanidine)
   Purpose: Ease abnormal muscle tone or movements reported in some individuals.
   Mechanism: Reduce spinal reflex hyperexcitability or central muscle tone. PubMed

4. Anticholinergic for dystonia (e.g., trihexyphenidyl)
   Purpose: Improve dystonic postures or cramps in selected cases.
   Mechanism: Balances acetylcholine–dopamine signaling in basal ganglia. PubMed

5. Botulinum toxin injections
   Purpose: Target troublesome focal dystonia or drooling.
   Mechanism: Temporarily blocks acetylcholine release at neuromuscular junctions. PubMed

6. Sleep aids (behavior first; meds if needed) (e.g., melatonin)
   Purpose: Improve sleep onset/maintenance; better sleep can reduce daytime symptoms and seizure risk.
   Mechanism: Circadian support via melatonin receptor signaling. MedlinePlus

7. Treatments for GERD if present (e.g., proton-pump inhibitors)
   Purpose: Ease reflux that can worsen feeding or sleep.
   Mechanism: Suppress gastric acid secretion to reduce esophageal irritation. MedlinePlus

8. Constipation management (e.g., polyethylene glycol, stool softeners)
   Purpose: Improve comfort and feeding tolerance.
   Mechanism: Osmotic action increases stool water content and frequency. MedlinePlus

9. Sialorrhea (drooling) therapy (e.g., glycopyrrolate)
   Purpose: Improve saliva control when problematic.
   Mechanism: Peripheral anticholinergic effect reduces salivary output. MedlinePlus

10. ADHD medications (e.g., methylphenidate) when attentional symptoms impair learning
    Purpose: Enhance focus and classroom function.
    Mechanism: Dopamine/norepinephrine reuptake inhibition in prefrontal cortex. MedlinePlus

11. Anxiety/depression treatments (e.g., SSRIs, CBT first)
    Purpose: Support mental health in older children/adults.
    Mechanism: Modulate serotonergic pathways; combine with therapy for best results. MedlinePlus

12. Analgesics (e.g., acetaminophen/ibuprofen as appropriate)
    Purpose: Pain relief for intercurrent illnesses or musculoskeletal discomfort.
    Mechanism: Central analgesia and COX inhibition. MedlinePlus

13. Antiemetics (e.g., ondansetron)
    Purpose: Control nausea that limits nutrition.
    Mechanism: 5-HT3 receptor antagonism. MedlinePlus

14. Allergy control (e.g., non-sedating antihistamines)
    Purpose: Improve sleep and comfort if allergic symptoms are present.
    Mechanism: H1 receptor blockade. MedlinePlus

15. Vitamin D and calcium when deficient
    Purpose: Support bone health, especially if mobility is limited.
    Mechanism: Corrects deficiency; not ACY1-specific. MedlinePlus

16. Iron therapy when iron-deficiency anemia is documented
    Purpose: Improve energy and development.
    Mechanism: Replenishes iron stores; monitor labs. MedlinePlus

17. Folate/B12 when deficient
    Purpose: Support hematologic and neurologic function.
    Mechanism: Corrects specific vitamin deficiencies. MedlinePlus

18. Rescue antipyretics during febrile illnesses
    Purpose: Lower fever that may trigger seizures.
    Mechanism: COX inhibition and hypothalamic set-point reduction. MedlinePlus

19. Topical therapies for drooling-related skin irritation
    Purpose: Protect skin integrity.
    Mechanism: Barrier creams reduce moisture damage. MedlinePlus

20. Standard immunizations and antivirals/antibiotics when indicated
    Purpose: Prevent and treat infections promptly.
    Mechanism: Reduce complications that can worsen neurologic symptoms. MedlinePlus

---

Dietary molecular supplements

There is no ACY1-specific supplement proven to change disease course. Use only to correct a documented deficiency or as part of balanced nutrition, under clinician/dietitian guidance.

1. Balanced essential amino acids from food
   Function/mechanism: Provide necessary building blocks for growth and repair; avoid unnecessary restriction since ACY1-specific benefit of protein restriction has not been shown. Medlink

2. Multivitamin at recommended daily allowance
   Function/mechanism: Covers general micronutrient needs if intake is limited; avoids megadoses without evidence. Medlink

3. Vitamin D (if low)
   Function/mechanism: Supports bone and immune function; dose individualized to blood levels. MedlinePlus

4. Calcium (if dietary intake is low)
   Function/mechanism: Bone mineralization; pair with vitamin D as needed. MedlinePlus

5. Omega-3 fatty acids (food-first)
   Function/mechanism: General support for cardiovascular and neurodevelopmental health; evidence is non-specific to ACY1D. MedlinePlus

6. Iron (only when deficient)
   Function/mechanism: Restores iron stores; improves anemia. MedlinePlus

7. Folate/B12 (if deficient)
   Function/mechanism: Corrects anemia and supports myelin and DNA synthesis. MedlinePlus

8. Fiber (dietary or supplement as needed)
   Function/mechanism: Supports bowel regularity and gut health. MedlinePlus

9. Probiotic foods
   Function/mechanism: May support gut comfort if constipation or reflux complicate feeding; ACY1-specific benefit unproven. MedlinePlus

10. Hydration strategies
    Function/mechanism: Adequate fluids help overall metabolism, bowel function, and temperature control. MedlinePlus

---

Immunity booster / regenerative / stem-cell drugs

There are no approved immune boosters, regenerative medicines, or stem-cell therapies for ACY1D. Any such products should be considered experimental and used only in IRB-approved clinical trials. Hypothetical future options may include gene-based treatments, but none are clinically available for this disorder today. GARD Information Center

---

Surgeries (when and why)

There is no surgery that corrects ACY1D. Rarely, surgery-adjacent procedures are used to manage difficult symptoms:

1. Vagus nerve stimulation (VNS) for drug-resistant epilepsy
   Why: To reduce seizure frequency when medicines are not enough. MedlinePlus

2. Gastrostomy tube (G-tube) for severe feeding problems or unsafe swallowing
   Why: To protect nutrition and reduce aspiration if oral feeding fails. MedlinePlus

3. Orthopedic procedures (e.g., tendon releases) for fixed contractures
   Why: To improve comfort, positioning, or care after conservative therapy fails. MedlinePlus

4. Botulinum toxin injections (procedural) for focal dystonia/sialorrhea
   Why: Targeted symptom relief when oral meds are ineffective or cause side effects. PubMed

5. Deep brain stimulation (DBS) (very select cases of severe dystonia)
   Why: To reduce disabling dystonia when other treatments fail; evidence is limited and case-based. PubMed

---

Prevention tips

1. Stay on routine care (metabolic, neurology, rehab).

2. Vaccinate on schedule to reduce infections that can trigger setbacks.

3. Have a written seizure/illness plan (home and school).

4. Treat fevers promptly and maintain hydration during illness.

5. Protect sleep with consistent routines.

6. Use safety gear and home modifications to prevent falls/injuries.

7. Healthy, balanced diet—avoid fad restrictions without clinician advice.

8. Regular therapy and home exercises to maintain skills.

9. Monitor growth and labs (nutrients, if advised).

10. Genetic counseling for family planning and carrier testing. MedlinePlus+1

---

When to see doctors urgently or soon

• Urgently / emergency: new or prolonged seizure; repeated vomiting with dehydration; trouble breathing; sudden loss of skills; severe injury or head trauma.

• Soon: increasing daytime sleepiness, worsening balance, new movement problems (dystonia/spasms), feeding difficulties, weight loss, behavior changes, persistent fevers, or concerns from teachers/therapists. MedlinePlus

---

What to eat & what to avoid

1. Eat: a regular, age-appropriate balanced diet with normal protein intake unless your metabolic team recommends otherwise. Avoid: self-imposed very low or very high protein diets. Medlink

2. Eat: fruits/vegetables, whole grains, lean proteins, and healthy fats. Avoid: excessive ultra-processed foods and sugary drinks. MedlinePlus

3. Eat: consistent meals and snacks for energy. Avoid: long fasts that worsen fatigue or irritability. MedlinePlus

4. Hydrate well. Avoid: dehydration, especially with fever/diarrhea. MedlinePlus

5. Include calcium and vitamin D sources (or supplements if deficient). Avoid: uncorrected deficiencies. MedlinePlus

6. Use fiber-rich foods for bowel regularity. Avoid: chronic low-fiber patterns causing constipation. MedlinePlus

7. If reflux is present, smaller meals and upright posture after eating. Avoid: late heavy meals. MedlinePlus

8. If a clinician suggests specific texture modifications for safety, follow them. Avoid: foods that pose choking/aspiration risk. MedlinePlus

9. Follow your dietitian’s individualized plan if growth issues arise. Avoid: supplement megadoses without medical advice. Medlink

10. Sick-day plan: easy fluids, simple foods, and early contact with your team. Avoid: handling prolonged illness alone. GARD Information Center

---

Frequently asked questions

1. How rare is ACY1D?
   Extremely rare; only a small number of cases have been reported worldwide, and the condition is likely under-diagnosed. PubMed

2. What causes it?
   Mutations in the ACY1 gene that reduce aminoacylase-1 enzyme activity. MedlinePlus

3. How is it inherited?
   Autosomal recessive—both parents are typically healthy carriers. NCBI

4. What are common signs?
   Variable: developmental delay, hypotonia, movement issues (including dystonia), seizures; some individuals are mildly affected or asymptomatic. MedlinePlus+1

5. How is it diagnosed?
   Urine organic acid testing that shows multiple N-acetyl amino acids, confirmed by ACY1 gene testing. PMC+1

6. Is there a cure?
   No specific cure today; treatment is supportive and symptom-directed. Medlink

7. Does diet fix it?
   No ACY1-specific dietary therapy is proven. Routine balanced nutrition is advised unless your specialist recommends something different. Medlink

8. Will my child walk or talk?
   Outcomes vary widely. Early therapies maximize potential and function. MedlinePlus

9. Can seizures be controlled?
   Often, yes—using standard epilepsy care and rescue plans when needed. MedlinePlus

10. Are there long-term complications?
    Depends on severity; many individuals do well with supportive care. Ongoing follow-up monitors development, learning, and movement. MedlinePlus

11. What tests monitor the condition?
    Developmental assessments, therapy evaluations, and targeted labs or imaging based on symptoms; some labs can quantify specific urinary N-acetyl amino acids. Mayo Clinic Laboratories

12. Should our family get genetic testing?
    Carrier and cascade testing can clarify risks for relatives and future pregnancies. MedlinePlus

13. Is there research?
    Yes—case reports and natural-history work continue; ask about registries and trials through your genetics team. PubMed

14. Could this be found on newborn screening?
    ACY1D is not a standard NBS target in most regions; many cases are found later after metabolic testing for symptoms. MedlinePlus

15. Which specialists do we need?
    Clinical genetics/metabolic specialists, neurology, physiatry/rehab, PT/OT/SLP, nutrition, psychology/psychiatry, social work, and school services as needed. GARD Information Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 15, 2025.

PDF Documents For This Disease Condition References